Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias.
The global Acute Intermittent Porphyria Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Acute Intermittent Porphyria Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Acute Intermittent Porphyria Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Acute Intermittent Porphyria Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Acute Intermittent Porphyria Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Abbott
...
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
350mg
313mg
Segment by Application
Hospital
Pharmacy
Summary:
Get latest Market Research Reports on Acute Intermittent Porphyria Drugs. Industry analysis & Market Report on Acute Intermittent Porphyria Drugs is a syndicated market report, published as Global Acute Intermittent Porphyria Drugs Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of Acute Intermittent Porphyria Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.